Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies

Evidence suggests that ARIAs are frequent, mostly asymptomatic collateral events of amyloid-modifying therapies, highlighting the need for standardized clinical and neuroradiological management protocols in real-world clinical settings.